Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test let some breast cancer patients stop treatment?

NCT ID NCT06450314

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether patients with HER2-positive metastatic breast cancer who have had their disease controlled for at least two years on anti-HER2 therapy can safely stop that treatment. Participants must also have no detectable cancer DNA in their blood (ctDNA-negative). The study monitors them closely with regular ctDNA tests and scans to see if the cancer stays under control without ongoing medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
discontinuation of anti-HER2 targeted therapy (trastuzumab, pertuzumab, trastuzumab-deruxtecan, T-DM1)
What this could lead to
If successful, this could allow some patients with HER2-positive metastatic breast cancer to safely stop long-term treatment without their cancer progressing.
What could go wrong
This is a small, early-phase study, and stopping therapy may lead to cancer recurrence. The approach relies on a blood test (ctDNA) that may not catch all signs of progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Centre Eugène marquis

    RECRUITING

    Rennes, 44229, France

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.